References
  1. J.A. Figueroa, A. Reidy, L. Mirandola, K. Trotter, N. Suvorava, A. Figueroa, V. Konala, A. Aulakh, L. Littlefield, F. Grizzi, R.L. Rahman, M.R. Jenkins, B. Musgrove, S. Radhi, N. D’Cunha, L.N. D’Cunha, P.L. Hermonat, E. Cobos, M. Chiriva-Internati, Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy, Int. Rev. Immunol. 34 (2015) 154-187. https://doi.org/10.3109/ 08830185.2015.1018419.
  2. V. Hillerdal, M. Essand, Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer, Biodrugs 29 (2015) 75-89. https://doi.org/10.1007/ s40259-015-0122-9.
  3. W. Zhang, CAR T-cell therapy: opportunities and challenges, Immunotherapy 8 (2016) 245-247. https://doi.org/10.2217/imt.15.129.
  4. C.H. June, R.S. O’Connor, O.U. Kawalekar, S. Ghassemi, M.C. Milone, CAR T cell immunotherapy for human cancer, Science 359 (2018) 1361-1365. https://doi.org/ 10.1126/science.aar6711.
  5. D.W. Lee, J.N. Kochenderfer, M. Stetler-Stevenson, Y.K. Cui, C. Delbrook, S.A. Feldman, T.J. Fry, R. Orentas, M. Sabatino, N.N. Shah, S.M. Steinberg, D. Stroncek, N. Tschernia, C. Yuan, H. Zhang, L. Zhang, S.A. Rosenberg, A.S. Wayne, C.L. Mackall, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, Lancet 385 (2015) 517-528. https://doi.org/10.1016/s0140-6736(14)61403-3.
  6. J. Liu, J.F. Zhong, X. Zhang, C. Zhang, Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies, J. Hematol. Oncol. 10 (2017) 35. https://doi.org/10.1186/s13045-017-0405-3.
  7. S. Stoiber, B.L. Cadilha, M.-R. Benmebarek, S. Lesch, S. Endres, S. Kobold, Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy, Cells 8 (2019). https://doi.org/10.3390/cells8050472.
  8. T.T. Byrd, K. Fousek, A. Pignata, C. Szot, H. Samaha, S. Seaman, L. Dobrolecki, V.S. Salsman, H.Z. Oo, K. Bielamowicz, D. Landi, N. Rainusso, J. Hicks, S. Powell, M.L. Baker, W.S. Wels, J. Koch, P.H. Sorensen, B. Deneen, M.J. Ellis, M.T. Lewis, M. Hegde, B.S. Fletcher, B. St Croix, N. Ahmed, TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer, Cancer Res. 78 (2018) 489-500. https://doi.org/10.1158/0008-5472.Can-16-1911.
  9. H. Du, K. Hirabayashi, S. Ahn, N.P. Kren, S.A. Montgomery, X. Wang, K. Tiruthani, B. Mirlekar, D. Michaud, K. Greene, S.G. Herrera, Y. Xu, C. Sun, Y. Chen, X. Ma, C.R. Ferrone, Y. Pylayeva-Gupta, J.J. Yeh, R. Liu, B. Savoldo, S. Ferrone, G. Dotti, Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells, Cancer Cell 35 (2019) 221-237 e228. https://doi.org/10.1016/j.ccell.2019.01.002.
  10. M.C. Ramello, I. Benzaïd, B.M. Kuenzi, M. Lienlaf-Moreno, W.M. Kandell, D.N. Santiago, M. Pabón-Saldaña, L. Darville, B. Fang, U. Rix, S. Yoder, A. Berglund, J.M. Koomen, E.B. Haura, D. Abate-Daga, An immunoproteomic approach to characterize the CAR interactome and signalosome, Science Signaling 12 (2019) eaap9777. https://doi.org/10.1126/scisignal.aap9777.
  11. C. Sun, P. Shou, H. Du, K. Hirabayashi, Y. Chen, L.E. Herring, S. Ahn, Y. Xu, K. Suzuki, G. Li, O. Tsahouridis, L. Su, B. Savoldo, G. Dotti, THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells, Cancer Cell 37 (2020) 216-225.e6. https://doi.org/10.1016/j.ccell.2019.12.014.
  12. J. Feucht, M. Sadelain, Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors, Immuno-Oncology Technology 8 (2020) 2-11. .
  13. S. Guedan, A.D. Posey, Jr., C. Shaw, A. Wing, T. Da, P.R. Patel, S.E. McGettigan, V. Casado-Medrano, O.U. Kawalekar, M. Uribe-Herranz, D. Song, J.J. Melenhorst, S.F. Lacey, J. Scholler, B. Keith, R.M. Young, C.H. June, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI Insight 3 (2018) e96976. https://doi.org/10.1172/jci.insight.96976.
  14. S.J. Priceman, E.A. Gerdts, D. Tilakawardane, K.T. Kennewick, J.P. Murad, A.K. Park, B. Jeang, Y. Yamaguchi, X. Yang, R. Urak, L. Weng, W.-C. Chang, S. Wright, S. Pal, R.E. Reiter, A.M. Wu, C.E. Brown, S.J. Forman, Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer, Oncoimmunology 7 (2017) e1380764-e1380764. https://doi.org/ 10.1080/2162402X.2017.1380764.
  15. S.R. Wiley, K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, et al., Identification and characterization of a new member of the TNF family that induces apoptosis, Immunity 3 (1995) 673-682. https://doi.org/10.1016/1074-7613(95)90057-8.
  16. D.I. Radke, Q. Ling, R. Häsler, G. Alp, H. Ungefroren, A. Trauzold, Downregulation of TRAIL-Receptor 1 Increases TGFβ Type II Receptor Expression and TGFβ Signalling Via MicroRNA-370-3p in Pancreatic Cancer Cells, Cancers (Basel) 10 (2018) 399. https://doi.org/10.3390/cancers10110399.
  17. A.W. Tolcher, M. Mita, N.J. Meropol, M. von Mehren, A. Patnaik, K. Padavic, M. Hill, T. Mays, T. McCoy, N.L. Fox, W. Halpern, A. Corey, R.B. Cohen, Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1, J. Clin. Oncol. 25 (2007) 1390-1395. .
  18. J. Shi, J. Li, Z. Xu, L. Chen, R. Luo, C. Zhang, F. Gao, J. Zhang, C. Fu, Celastrol: A Review of Useful Strategies Overcoming its Limitation in Anticancer Application, Front. Pharmacol. 11 (2020) 558741. https://doi.org/10.3389/fphar.2020.558741.
  19. A. Jin, T. Ozawa, K. Tajiri, Z. Lin, T. Obata, I. Ishida, H. Kishi, A. Muraguchi, Generation of TRAIL-receptor 1-specific human monoclonal Ab by a combination of immunospot array assay on a chip and human Ab-producing mice, Eur. J. Immunol. 40 (2010) 3591-3593. https://doi.org/10.1002/eji.201040551.
  20. S. Kaveri, T. Ozawa, X. Piao, E. Kobayashi, Y. Zhou, H. Sakurai, T. Andoh, A. Jin, H. Kishi, A. Muraguchi, A Novel Rabbit Immunospot Array Assay on a Chip Allows for the Rapid Generation of Rabbit Monoclonal Antibodies with High Affinity, PLoS ONE 7 (2012) e52383. https://doi.org/10.1371/journal.pone.0052383.
  21. Z. Hao, X. Han, X. Sun, M. Shen, J. Huang, Y. Li, T. Ozawa, D. Pang, S. Jin, H. Kishi, A. Muraguchi, A. Jin, Fully human monoclonal antibodies to TRAIL-R1 enhance TRAIL-induced apoptosis via activation of caspase-8 pathway, Biochem. Biophys. Res. Commun. 475 (2016) 238-244. https://doi.org/10.1016/j.bbrc.2016.05.089.
  22. H. Wajant, D. Moosmayer, T. Wüest, T. Bartke, E. Gerlach, U. Schönherr, N. Peters, P. Scheurich, K. Pfizenmaier, Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative, Oncogene 20 (2001) 4101-4106. https://doi.org/10.1038/ sj.onc.1204558.
  23. F. Dufour, T. Rattier, A.A. Constantinescu, L. Zischler, A. Morlé, H. Ben Mabrouk, E. Humblin, G. Jacquemin, E. Szegezdi, F. Delacote, N. Marrakchi, G. Guichard, C. Pellat-Deceunynck, P. Vacher, P. Legembre, C. Garrido, O. Micheau, TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress, Oncotarget 8 (2017) 9974-9985. https://doi.org/10.18632/oncotarget.14285.
  24. G. Gross, T. Waks, Z. Eshhar, Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 10024-10028. https://doi.org/10.1073/pnas.86.24.10024.
  25. B.A. Irving, A. Weiss, The cytoplasmic domain of the T-cellreceptor zeta-chain is sufficient to couple to receptor-associated singal transduction pathways, Cell 64 (1991) 891-901. https://doi.org/10.1016/0092-8674(91)90314-o.
  26. B. Jonsson, G. Liminga, K. Csoka, H. Fridborg, S. Dhar, P. Nygren, R. Larsson, Cytotoxic activity of calcein acetoxymethyl ester (Calcein/AM) on primary cultures of human haematological and solid tumours, Eur. J. Cancer 32a (1996) 883-887. https://doi.org/10.1016/0959-8049(96)00015-9.
  27. M. Bilandzic, A. Rainczuk, E. Green, N. Fairweather, T.W. Jobling, M. Plebanski, A.N. Stephens, Keratin-14 (KRT14) Positive Leader Cells Mediate Mesothelial Clearance and Invasion by Ovarian Cancer Cells, Cancers (Basel) 11 (2019) 1228. https://doi.org/10.3390/cancers11091228.
  28. P. Schneider, J.L. Bodmer, M. Thome, K. Hofmann, N. Holler, J. Tschopp, Characterization of two receptors for TRAIL, FEBS Lett. 416 (1997) 329-334. https://doi.org/10.1016/s0014-5793(97)01231-3.
  29. S.-Y. Park, H.-H. Park, S.-Y. Park, S.M. Hong, S. Yoon, M.J. Morgan, Y.-S. Kim, Reduction in MLKL-mediated endosomal trafficking enhances the TRAIL-DR4/5 signal to increase cancer cell death, Cell Death. Dis. 11 (2020) 744-744. https://doi.org/ 10.1038/s41419-020-02941-9.
  30. D. Wang, Y. Shao, X. Zhang, G. Lu, B. Liu, IL-23 and PSMA-targeted duo-CAR T cells in Prostate Cancer Eradication in a preclinical model, J. Transl. Med. 18 (2020) 23-23. https://doi.org/10.1186/s12967-019-02206-w.
  31. R. Saleh, S.M. Toor, D. Al-Ali, V. Sasidharan Nair, E. Elkord, Blockade of PD-1, PD-L1, and TIM-3 Altered Distinct Immune- and Cancer-Related Signaling Pathways in the Transcriptome of Human Breast Cancer Explants, Genes (Basel) 11 (2020) 703. https://doi.org/10.3390/genes11060703.
  32. M. Siegemund, O. Seifert, M. Zarani, T. Džinić, V. De Leo, D. Göttsch, S. Münkel, M. Hutt, K. Pfizenmaier, R.E. Kontermann, An optimized antibody-single-chain TRAIL fusion protein for cancer therapy, MAbs 8 (2016) 879-891. https://doi.org/10.1080/ 19420862.2016.1172163.
  33. S. Rafiq, O.O. Yeku, H.J. Jackson, T.J. Purdon, D.G. van Leeuwen, D.J. Drakes, M. Song, M.M. Miele, Z. Li, P. Wang, S. Yan, J. Xiang, X. Ma, V.E. Seshan, R.C. Hendrickson, C. Liu, R.J. Brentjens, Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo, Nat. Biotechnol. 36 (2018) 847-856. https://doi.org/10.1038/nbt.4195.
  34. C. Tong, Y. Zhang, Y. Liu, X. Ji, W. Zhang, Y. Guo, X. Han, D. Ti, H. Dai, C. Wang, Q. Yang, W. Liu, Y. Wang, Z. Wu, W. Han, Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma, Blood 136 (2020) 1632-1644. https://doi.org/10.1182/blood.2020005278.
  35. K. Adachi, Y. Kano, T. Nagai, N. Okuyama, Y. Sakoda, K. Tamada, IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor, Nat. Biotechnol. 36 (2018) 346-351. https://doi.org/10.1038/nbt.4086.
  36. S. Voigt, S. Philipp, P. Davarnia, S. Winoto-Morbach, C. Röder, C. Arenz, A. Trauzold, D. Kabelitz, S. Schütze, H. Kalthoff, D. Adam, TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells, BMC Cancer 14 (2014) 74. https://doi.org/ 10.1186/1471-2407-14-74.
  37. A.C. Boroughs, R.C. Larson, B.D. Choi, A.A. Bouffard, L.S. Riley, E. Schiferle, A.S. Kulkarni, C.L. Cetrulo, D. Ting, B.R. Blazar, S. Demehri, M.V. Maus, Chimeric antigen receptor costimulation domains modulate human regulatory T cell function, JCI insight 5 (2019) e126194. https://doi.org/10.1172/jci.insight.126194 .
  38. X. Meng, R. Jing, L. Qian, C. Zhou, J. Sun, Engineering Cytoplasmic Signaling of CD28ζ CARs for Improved Therapeutic Functions, Front. Immunol. 11 (2020) 1046. https://doi.org/10.3389/fimmu.2020.01046.
  39. S. Guedan, A.D. Posey, Jr., C. Shaw, A. Wing, T. Da, P.R. Patel, S.E. McGettigan, V. Casado-Medrano, O.U. Kawalekar, M. Uribe-Herranz, D. Song, J.J. Melenhorst, S.F. Lacey, J. Scholler, B. Keith, R.M. Young, C.H. June, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation, JCI insight 3 (2018) e96976. https://doi.org/10.1172/jci.insight.96976.
  40. G. Li, J.C. Boucher, H. Kotani, K. Park, Y. Zhang, B. Shrestha, X. Wang, L. Guan, N. Beatty, D. Abate-Daga, M.L. Davila, 4-1BB enhancement of CAR T function requires NF-κB and TRAFs, JCI insight 3 (2018) e121322. https://doi.org/10.1172/ jci.insight.121322.